These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25224321)

  • 1. Association of increased levels of TGF-β1 and p14ARF in prostate carcinoma cell lines overexpressing Egr-1.
    Parra E; Gutiérrez L; Ferreira J
    Oncol Rep; 2014 Nov; 32(5):2191-8. PubMed ID: 25224321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer.
    Jin Y; Cui Z; Li X; Jin X; Peng J
    Oncotarget; 2017 Apr; 8(16):26090-26099. PubMed ID: 28212533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of Egr-1 by siRNA inhibits growth of human prostate carcinoma cell line PC-3.
    Parra E; Ortega A; Saenz L
    Oncol Rep; 2009 Dec; 22(6):1513-8. PubMed ID: 19885607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
    Guo Y; Kyprianou N
    Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of EGR-1 modulates the activity of NF-κB and AP-1 in prostate carcinoma PC-3 and LNCaP cell lines.
    Parra E; Ferreira J; Ortega A
    Int J Oncol; 2011 Aug; 39(2):345-52. PubMed ID: 21617851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor β1 (TGF-β1) suppresses growth of B-cell lymphoma cells by p14(ARF)-dependent regulation of mutant p53.
    Chen G; Ghosh P; O'Farrell T; Munk R; Rezanka LJ; Sasaki CY; Longo DL
    J Biol Chem; 2012 Jun; 287(27):23184-95. PubMed ID: 22621932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Growth Response Protein-1 Involves in Transforming Growth factor-β1 Induced Epithelial-Mesenchymal Transition and Inhibits Migration of Non-Small-Cell Lung Cancer Cells.
    Shan LN; Song YG; Su D; Liu YL; Shi XB; Lu SJ
    Asian Pac J Cancer Prev; 2015; 16(9):4137-42. PubMed ID: 25987100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of p21Waf1/Cip1 and JNK with costimulation of prostate cancer cell activation by an siRNA Egr-1 inhibitor.
    Parra E; Gutiérrez L; Ferreira J
    Oncol Rep; 2013 Aug; 30(2):911-6. PubMed ID: 23715767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Egr-1 by siRNA in prostate carcinoma cell lines is associated with decreased expression of AP-1 and NF-κB.
    Parra E; Ferreira J; Saenz L
    Int J Mol Med; 2011 Nov; 28(5):847-53. PubMed ID: 21743958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigallocatechin-3-gallate inhibits transforming-growth-factor-β1-induced collagen synthesis by suppressing early growth response-1 in human buccal mucosal fibroblasts.
    Hsieh YP; Chen HM; Lin HY; Yang H; Chang JZ
    J Formos Med Assoc; 2017 Feb; 116(2):107-113. PubMed ID: 26922429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
    Guo Y; Kyprianou N
    Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of lnRNA-NEF is involved in the postoperative cancer distant recurrence in prostate carcinoma patients.
    Wan X; Xiang J; Zhang Q; Bian C
    J Cell Biochem; 2019 Jun; 120(6):9601-9607. PubMed ID: 30556255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
    Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
    Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Klotho down-regulates Egr-1 by inhibiting TGF-β1/Smad3 signaling in high glucose treated human mesangial cells.
    Li Y; Hu F; Xue M; Jia YJ; Zheng ZJ; Wang L; Guan MP; Xue YM
    Biochem Biophys Res Commun; 2017 May; 487(2):216-222. PubMed ID: 28411025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased c-Abl activity in PC-3 and LNCaP prostate cancer cells overexpressing the early growth response-1 protein.
    Parra E; Ferreira J; Gutierrez L
    Oncol Rep; 2014 Jan; 31(1):422-7. PubMed ID: 24190424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of KLF14 and egr-1 in the TGF-beta1 action on Leydig cell proliferation.
    Gonzalez CR; Vallcaneras SS; Calandra RS; Gonzalez Calvar SI
    Cytokine; 2013 Feb; 61(2):670-5. PubMed ID: 23317878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of TGF-beta1 gene transcription in human prostate cancer cells by nitric oxide.
    Wang D; Lu S; Dong Z
    Prostate; 2007 Dec; 67(16):1825-33. PubMed ID: 17941092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of transforming growth factor type III receptor restores TGF-β1 sensitivity in human tongue squamous cell carcinoma cells.
    Li D; Xu D; Lu Z; Dong X; Wang X
    Biosci Rep; 2015 Jul; 35(4):. PubMed ID: 26205654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells.
    Lu S; Dong Z
    Prostate; 2006 Jun; 66(9):996-1004. PubMed ID: 16541418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opposite functions of HIF-α isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions.
    Chae KS; Kang MJ; Lee JH; Ryu BK; Lee MG; Her NG; Ha TK; Han J; Kim YK; Chi SG
    Oncogene; 2011 Mar; 30(10):1213-28. PubMed ID: 21057546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.